196 related articles for article (PubMed ID: 32949955)
1. Discovery of (E)-N-(4-methyl-5-(3-(2-(pyridin-2-yl)vinyl)-1H-indazol-6-yl)thiazol-2-yl)-2-(4-methylpiperazin-1-yl)acetamide (IHMT-TRK-284) as a novel orally available type II TRK kinase inhibitor capable of overcoming multiple resistant mutants.
Wang B; Zhang W; Liu X; Zou F; Wang J; Liu Q; Wang A; Hu Z; Chen Y; Qi S; Jiang Z; Chen C; Hu C; Wang L; Wang W; Liu Q; Liu J
Eur J Med Chem; 2020 Dec; 207():112744. PubMed ID: 32949955
[TBL] [Abstract][Full Text] [Related]
2. Discovery of (E)-N-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)-3-((3-(2-(pyridin-2-yl)vinyl)-1H-indazol-6-yl)thio)propanamide (CHMFL-ABL-121) as a highly potent ABL kinase inhibitor capable of overcoming a variety of ABL mutants including T315I for chronic myeloid leukemia.
Liu X; Wang B; Chen C; Jiang Z; Hu C; Wu H; Zhang Y; Liu X; Wang W; Wang J; Hu Z; Wang A; Huang T; Liu Q; Wang W; Wang L; Wang W; Ren T; Li L; Xia R; Ge J; Liu Q; Liu J
Eur J Med Chem; 2018 Dec; 160():61-81. PubMed ID: 30317026
[TBL] [Abstract][Full Text] [Related]
3. Structural Optimization and Structure-Activity Relationship Studies of 6,6-Dimethyl-4-(phenylamino)-6
Pan S; Zhang L; Luo X; Nan J; Yang W; Bin H; Li Y; Huang Q; Wang T; Pan Z; Mu B; Wang F; Tian C; Liu Y; Li L; Yang S
J Med Chem; 2022 Feb; 65(3):2035-2058. PubMed ID: 35080890
[TBL] [Abstract][Full Text] [Related]
4. Discovery of ( E)- N
Liu X; Wang B; Chen C; Qi Z; Zou F; Wang J; Hu C; Wang A; Ge J; Liu Q; Yu K; Hu Z; Jiang Z; Wang W; Wang L; Wang W; Ren T; Bai M; Liu Q; Liu J
J Med Chem; 2019 May; 62(10):5006-5024. PubMed ID: 31046271
[TBL] [Abstract][Full Text] [Related]
5. NTRK kinase domain mutations in cancer variably impact sensitivity to type I and type II inhibitors.
Somwar R; Hofmann NE; Smith B; Odintsov I; Vojnic M; Linkov I; Tam A; Khodos I; Mattar MS; de Stanchina E; Flynn D; Ladanyi M; Drilon A; Shinde U; Davare MA
Commun Biol; 2020 Dec; 3(1):776. PubMed ID: 33328556
[TBL] [Abstract][Full Text] [Related]
6. Discovery of 2-(4-Chloro-3-(trifluoromethyl)phenyl)-
Wu Y; Wang B; Wang J; Qi S; Zou F; Qi Z; Liu F; Liu Q; Chen C; Hu C; Hu Z; Wang A; Wang L; Wang W; Ren T; Cai Y; Bai M; Liu Q; Liu J
J Med Chem; 2019 Jul; 62(13):6083-6101. PubMed ID: 31250638
[TBL] [Abstract][Full Text] [Related]
7. Design and synthesis of novel orally selective and type II pan-TRK inhibitors to overcome mutations by property-driven optimization.
Li MC; Lin WH; Wang PC; Su YC; Chen PY; Fan CM; Chen CP; Huang CL; Chiu CH; Chang L; Chen CT; Yeh TK; Hsieh HP
Eur J Med Chem; 2021 Nov; 224():113673. PubMed ID: 34303872
[TBL] [Abstract][Full Text] [Related]
8. Discovery of novel 3-(1H-pyrazol-4-yl)-1H-indazole derivatives as potent type II TRK inhibitors against acquired resistance.
Qin Q; Guo Z; Lu S; Wang X; Fu Q; Wu T; Sun Y; Liu N; Zhang H; Zhao D; Cheng M
Eur J Med Chem; 2024 Jan; 264():115953. PubMed ID: 38029466
[TBL] [Abstract][Full Text] [Related]
9. Discovery of 4-(((4-(5-chloro-2-(((1s,4s)-4-((2-methoxyethyl)amino)cyclohexyl)amino)pyridin-4-yl)thiazol-2-yl)amino)methyl)tetrahydro-2H-pyran-4-carbonitrile (JSH-150) as a novel highly selective and potent CDK9 kinase inhibitor.
Wang B; Wu J; Wu Y; Chen C; Zou F; Wang A; Wu H; Hu Z; Jiang Z; Liu Q; Wang W; Zhang Y; Liu F; Zhao M; Hu J; Huang T; Ge J; Wang L; Ren T; Wang Y; Liu J; Liu Q
Eur J Med Chem; 2018 Oct; 158():896-916. PubMed ID: 30253346
[TBL] [Abstract][Full Text] [Related]
10. Design, synthesis, and Structure-Activity Relationships (SAR) of 3-vinylindazole derivatives as new selective tropomyosin receptor kinases (Trk) inhibitors.
Duan Y; Wang J; Zhu S; Tu ZC; Zhang Z; Chan S; Ding K
Eur J Med Chem; 2020 Oct; 203():112552. PubMed ID: 32702585
[TBL] [Abstract][Full Text] [Related]
11. Discovery of 3-pyrazolyl-substituted pyrazolo[1,5-a]pyrimidine derivatives as potent TRK inhibitors to overcome clinically acquired resistance.
Gong Y; Wu FX; Wang MS; Xu HC; Zhuo LS; Yang GF; Huang W
Eur J Med Chem; 2022 Nov; 241():114654. PubMed ID: 35961071
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetic-Pharmacodynamic-Efficacy Modeling of ONO-7579, a Novel Pan-Tropomyosin Receptor Kinase Inhibitor, in a Murine Xenograft Tumor Model.
Iida H; Fujikawa R; Kozaki R; Harada R; Hosokawa Y; Ogawara KI; Ohno T
J Pharmacol Exp Ther; 2020 Jun; 373(3):361-369. PubMed ID: 32217770
[TBL] [Abstract][Full Text] [Related]
13. A Next-Generation TRK Kinase Inhibitor Overcomes Acquired Resistance to Prior TRK Kinase Inhibition in Patients with TRK Fusion-Positive Solid Tumors.
Drilon A; Nagasubramanian R; Blake JF; Ku N; Tuch BB; Ebata K; Smith S; Lauriault V; Kolakowski GR; Brandhuber BJ; Larsen PD; Bouhana KS; Winski SL; Hamor R; Wu WI; Parker A; Morales TH; Sullivan FX; DeWolf WE; Wollenberg LA; Gordon PR; Douglas-Lindsay DN; Scaltriti M; Benayed R; Raj S; Hanusch B; Schram AM; Jonsson P; Berger MF; Hechtman JF; Taylor BS; Andrews S; Rothenberg SM; Hyman DM
Cancer Discov; 2017 Sep; 7(9):963-972. PubMed ID: 28578312
[TBL] [Abstract][Full Text] [Related]
14. Discovery and characterization of a novel highly potent and selective type II native and drug-resistant V299L mutant BCR-ABL inhibitor (CHMFL-ABL-039) for Chronic Myeloid Leukemia (CML).
Wu J; Wang A; Li X; Chen C; Qi Z; Hu C; Wang W; Wu H; Huang T; Zhao M; Wang W; Hu Z; Liu Q; Wang B; Wang L; Li L; Ge J; Ren T; Xia R; Liu J; Liu Q
Cancer Biol Ther; 2019; 20(6):877-885. PubMed ID: 30894066
[TBL] [Abstract][Full Text] [Related]
15. Discovery of pyrazolo-thieno[3,2-d]pyrimidinylamino-phenyl acetamides as type-II pan-tropomyosin receptor kinase (TRK) inhibitors: Design, synthesis, and biological evaluation.
Yan W; Zhang L; Lv F; Moccia M; Carlomagno F; Landry C; Santoro M; Gosselet F; Frett B; Li HY
Eur J Med Chem; 2021 Apr; 216():113265. PubMed ID: 33652352
[TBL] [Abstract][Full Text] [Related]
16. Discovery of Entrectinib: A New 3-Aminoindazole As a Potent Anaplastic Lymphoma Kinase (ALK), c-ros Oncogene 1 Kinase (ROS1), and Pan-Tropomyosin Receptor Kinases (Pan-TRKs) inhibitor.
Menichincheri M; Ardini E; Magnaghi P; Avanzi N; Banfi P; Bossi R; Buffa L; Canevari G; Ceriani L; Colombo M; Corti L; Donati D; Fasolini M; Felder E; Fiorelli C; Fiorentini F; Galvani A; Isacchi A; Borgia AL; Marchionni C; Nesi M; Orrenius C; Panzeri A; Pesenti E; Rusconi L; Saccardo MB; Vanotti E; Perrone E; Orsini P
J Med Chem; 2016 Apr; 59(7):3392-408. PubMed ID: 27003761
[TBL] [Abstract][Full Text] [Related]
17. Discovery of the First Highly Selective and Broadly Effective Macrocycle-Based Type II TRK Inhibitors that Overcome Clinically Acquired Resistance.
Wang Z; Wang J; Wang Y; Xiang S; Song X; Tu Z; Zhou Y; Zhang ZM; Zhang Z; Ding K; Lu X
J Med Chem; 2022 Apr; 65(8):6325-6337. PubMed ID: 35426680
[TBL] [Abstract][Full Text] [Related]
18. Structure-Based Optimization of the Third Generation Type II Macrocycle TRK Inhibitors with Improved Activity against Solvent-Front, xDFG, and Gatekeeper Mutations.
Wang Z; Wang J; Wang Y; Xiang S; Zhou H; Song S; Song X; Tu Z; Zhou Y; Ding K; Zhang ZM; Zhang Z; Lu X
J Med Chem; 2023 Sep; 66(18):12950-12965. PubMed ID: 37676745
[TBL] [Abstract][Full Text] [Related]
19. Discovery of 4-methyl-N-(4-((4-methylpiperazin- 1-yl)methyl)-3-(trifluoromethyl)phenyl)-3-((6-(pyridin-3-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl)-oxy)benzamide as a potent inhibitor of RET and its gatekeeper mutant.
Li X; Su J; Yang Y; Lian W; Deng Z; Yang Z; Chen G; Zhang B; Dong C; Liu X; Li L; Wang Z; Hu Z; Xu Q; Deng X
Eur J Med Chem; 2020 Dec; 207():112755. PubMed ID: 32882611
[TBL] [Abstract][Full Text] [Related]
20. Identification and preclinical characterization of AZ-23, a novel, selective, and orally bioavailable inhibitor of the Trk kinase pathway.
Thress K; Macintyre T; Wang H; Whitston D; Liu ZY; Hoffmann E; Wang T; Brown JL; Webster K; Omer C; Zage PE; Zeng L; Zweidler-McKay PA
Mol Cancer Ther; 2009 Jul; 8(7):1818-27. PubMed ID: 19509272
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]